OKYO Pharma (OKYO) Total Current Liabilities (2021 - 2026)
OKYO Pharma (OKYO) posted quarterly Total Current Liabilities of $8.6 million for Q1 2026, down 6.35% year-over-year from $9.2 million in Q1 2025, and up 7.22% quarter-over-quarter from $8.1 million in Q3 2025.
OKYO Pharma (OKYO) Total Current Liabilities (2021 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Total Current Liabilities for 6 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 6.35% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $8.6 million (down 6.35% YoY), while the FY2026 annual figure was $8.6 million, down 6.35% from the prior year.
- Total Current Liabilities climbed to $8.6 million in Q1 2026 per OKYO's latest filing, from $8.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $10.1 million in Q3 2024 and bottomed at $1.4 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $7.5 million across 5 years, with a median of $8.2 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities retreated 20.74% — and 2023, when it jumped 436.3%.
- OKYO Pharma's Total Current Liabilities stood at $1.4 million in 2022, then surged by 514.52% to $8.3 million in 2023, then climbed by 20.91% to $10.1 million in 2024, then dropped by 19.85% to $8.1 million in 2025, then climbed by 7.22% to $8.6 million in 2026.
- Business Quant data shows OKYO's Total Current Liabilities at $8.6 million in Q1 2026, $8.1 million in Q3 2025, and $9.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 630.93 Mn |
| 10 | OKYO Pharma | 1.49 Bn | 1.49 Bn | - | 8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.64 Mn |
| Sep 30, 2025 | 8.06 Mn |
| Mar 31, 2025 | 9.23 Mn |
| Sep 30, 2024 | 10.05 Mn |
| Mar 31, 2024 | 7.42 Mn |
| Sep 30, 2023 | 8.32 Mn |
| Mar 31, 2023 | 7.26 Mn |
| Mar 31, 2022 | 1.35 Mn |
| Mar 31, 2021 | 1.71 Mn |